摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3,3-二甲基哌嗪-1-甲酸叔丁酯 | 259808-67-8

中文名称
3,3-二甲基哌嗪-1-甲酸叔丁酯
中文别名
1-Boc-3,3-二甲基哌嗪
英文名称
tert-butyl 3,3-dimethylpiperazine-1-carboxylate
英文别名
3,3-dimethyl-piperazine-1-carboxylic acid tert-butyl ester;tert-butyl 3,3-dimethylpiperazin-1-carboxylate;1-Boc-3,3-dimethyl-piperazine
3,3-二甲基哌嗪-1-甲酸叔丁酯化学式
CAS
259808-67-8
化学式
C11H22N2O2
mdl
——
分子量
214.308
InChiKey
LBAIYWWWORXVEQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    275.1±15.0 °C(Predicted)
  • 密度:
    0.977±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.1
  • 重原子数:
    15
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.91
  • 拓扑面积:
    41.6
  • 氢给体数:
    1
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2933599090
  • 危险性防范说明:
    P261,P280,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H332,H335
  • 储存条件:
    2-8°C

SDS

SDS:e96cb1af6cfbf6d6bface75e7477cf8f
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: tert-Butyl 3,3-dimethylpiperazine-1-carboxylate
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: tert-Butyl 3,3-dimethylpiperazine-1-carboxylate
CAS number: 259808-67-8

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H22N2O2
Molecular weight: 214.3

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3,3-二甲基哌嗪-1-甲酸叔丁酯potassium carbonate 、 sodium hydroxide 作用下, 以 乙醇丙酮甲苯 为溶剂, 反应 25.0h, 生成 4-((1R,3S)-6-chloro-3-(phenyl-d5)-indan-1-yl)-1(d3),2,2-trimethylpiperazine fumarate
    参考文献:
    名称:
    [EN] 6-CHLORO-3-(PHENYL-D5)-INDEN-1-ONE AND USE THEREOF
    [FR] 6-CHLORO-3-(PHÉNYL-D5)-INDÉN-1-ONE ET SON UTILISATION
    摘要:
    公开号:
    WO2014096151A3
  • 作为产物:
    参考文献:
    名称:
    CVT-4325: a potent fatty acid oxidation inhibitor with favorable oral bioavailability
    摘要:
    New inhibitors of palmitoyl-CoA oxidation are based on the introduction of nitrogen heterocycles in the 'Western Portion' of the molecule. SAR studies led to the discovery of CVT-4325 (shown), a potent FOXi (IC50 = 380 nM rat mitochondria) with favorable PK properties (F= 93%, t(1/2) = 13.6 h, dog). (C) 2004 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2004.09.077
点击查看最新优质反应信息

文献信息

  • [EN] BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY<br/>[FR] COMPOSÉS HÉTÉROARYLE BICYCLIQUES UTILES EN TANT QU'INHIBITEURS DE LA VOIE DE SIGNALISATION PAR-2
    申请人:VERTEX PHARMA
    公开号:WO2016154075A1
    公开(公告)日:2016-09-29
    The compounds of formula I, wherein the variables are as defined herein, and pharmaceutically acceptable salts thereof are useful as inhibitors of the PAR-2 signaling pathway. The compounds of formula I and pharmaceutically acceptable compositions comprising such compounds can be employed for treating various diseases, disorders, and conditions.
    式I的化合物,其中变量如本文所定义,并且其药学上可接受的盐可用作PAR-2信号通路的抑制剂。式I的化合物和包含这些化合物的药学上可接受的组合物可用于治疗各种疾病、疾病和症状。
  • [EN] AMIDES AS PIM INHIBITORS<br/>[FR] AMIDES CONVENANT COMME INHIBITEURS DES PIM
    申请人:AMGEN INC
    公开号:WO2013130660A1
    公开(公告)日:2013-09-06
    The invention relates to amide-containing compounds of formula (1), and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pim kinase related conditions and diseases, preferably cancer.
    本发明涉及式(1)的含酰胺化合物及其盐。在一些实施例中,本发明涉及Pim-1和/或Pim-2和/或Pim-3蛋白激酶活性或酶功能的抑制剂或调节剂。在更进一步的实施例中,本发明涉及包含本文披露的化合物的药物组合物,及其用于预防治疗Pim激酶相关状况和疾病,尤其是癌症的应用。
  • [EN] PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE PURINE UTILES COMME INHIBITEURS DE PI3 KINASE
    申请人:HOFFMANN LA ROCHE
    公开号:WO2009053716A1
    公开(公告)日:2009-04-30
    This invention provides a compound which is a purine of formula (Ia) or (Ib): and the pharmaceutically acceptable salts thereof that are inhibitors of PI3K and a selective for the p110δ isoform, which is a class Ia PI3 kinase, over other class Ia PI3 kinases and over class Ib kinases. The compounds may be used to treat diseases and disorders arisi from abnormal cell growth, function or behaviour associated with PI3 kinase such as cance immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.
    这项发明提供了一种化合物,其为式(Ia)或(Ib)的嘌呤类化合物:及其药学上可接受的盐,这些化合物是PI3K的抑制剂,并且对p110δ同工型具有选择性,p110δ是Ia类PI3激酶,优于其他Ia类PI3激酶和Ib类激酶。这些化合物可用于治疗由于与PI3激酶相关的异常细胞生长、功能或行为引起的疾病和紊乱,如癌症、免疫紊乱、心血管疾病、病毒感染、炎症、代谢/内分泌功能紊乱和神经系统疾病。
  • [EN] HETEROARYLBENZIMIDAZOLE COMPOUNDS<br/>[FR] COMPOSÉS HÉTÉROARYLBENZIMIDAZOLE
    申请人:BAYER PHARMA AG
    公开号:WO2017102091A1
    公开(公告)日:2017-06-22
    The present invention covers heteroarylbenzimidazole compounds of general formula (I) in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative and/or inflammatory disorders, as a sole agent or in combination with other active ingredients.
    本发明涵盖了一般式(I)中的杂环芳基苯并咪唑化合物,其中R1、R2、R3、R4和R5如本文所定义,制备所述化合物的方法,用于制备所述化合物的有用中间体化合物,包括所述化合物的药物组合物和组合物,以及利用所述化合物制造用于治疗或预防疾病的药物组合物,特别是治疗或预防过度增殖和/或炎症性疾病的药物组合物,作为唯一活性成分或与其他活性成分组合使用。
  • HPK1 ANTAGONISTS AND USES THEREOF
    申请人:Nimbus Saturn, Inc.
    公开号:US20210078996A1
    公开(公告)日:2021-03-18
    The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
    本发明提供了化合物、其组合物以及使用这些化合物用于抑制HPK1和治疗HPK1介导的疾病的方法。
查看更多